More Screening Needed Before Non-Cardiac Surgery

According to this recent document by the American Heart Association (AHA), troponin should be monitored for at least 3 days after surgery.

Más screening es necesario previo a una cirugía cardíaca

With about 20% of patients (most of them, asymptomatic) showing elevated troponin after a non-cardiac surgery, this new AHA document recommends monitoring, for at least two days, patients with moderate to severe ischemia.

Myocardial injury after non-cardiac surgery was first associated with increased mortality in 2014. At the time, researchers interpreted that these events could be triggered by an increased burden of risk factors, including patients over 75 years of age with sleep apnea, anemia, cardiac failure, diabetes, and hypertension.

The moral of this work would be that myocardial injury after non-cardiac surgery is frequent, silent, and fatal—so it should be taken into account.

Current evidence shows that patients who develop injury have four times higher 30-day mortality, and about 90% of this population has no identifiable symptoms.

Given that most subjects develop symptoms within 24 hours, the document suggests dosing troponins for 48 to 72 hours in patients at moderately high risk.


Read also: Hypertensive Patients: Maximizing Doses or Adding New Drugs.


The idea of performing ischemia-evoking tests prior to non-cardiac surgery left us without much to do if a patient with normal results developed an injury. Now we can comprehend the elevation and re-stratify patients, reducing their future risk.

Post-surgical injury should end in a direct referral to a cardiologist to evaluate the indication for aspirin and lifestyle changes. Patient could interpret this as secondary prevention.

CIR-0000000000001024

Original Title: Diagnosis and management of patients with myocardial injury after noncardiac surgery: a scientific statement from the American Heart Association.

Reference: Kurt Ruetzler et al. Circulation. 2021 Oct 4;CIR0000000000001024. Online ahead of print. doi: 10.1161/CIR.0000000000001024. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...